Announcement • Dec 19
TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 4.2 million. TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 4.2 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 87,274,663
Price\Range: AUD 0.008
Discount Per Security: AUD 0.00048
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 437,725,337
Price\Range: AUD 0.008
Discount Per Security: AUD 0.00048
Transaction Features: Subsequent Direct Listing Announcement • Oct 27
TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 0.698197 million. TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 0.698197 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 87,274,663
Price\Range: AUD 0.008
Discount Per Security: AUD 0.00048
Transaction Features: Subsequent Direct Listing Announcement • Oct 16
TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 0.698197 million. TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 0.698197 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 87,274,663
Price\Range: AUD 0.008
Discount Per Security: AUD 0.00048
Transaction Features: Subsequent Direct Listing Announcement • Sep 26
TrivarX Limited, Annual General Meeting, Nov 21, 2025 TrivarX Limited, Annual General Meeting, Nov 21, 2025. Location: at the companys registered office, at 647 beaufort street, mount lawley, Australia New Risk • Aug 30
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$2.3m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$2.3m free cash flow). Share price has been highly volatile over the past 3 months (20% average weekly change). Shareholders have been substantially diluted in the past year (36% increase in shares outstanding). Revenue is less than US$1m (AU$1.1m revenue, or US$739k). Market cap is less than US$10m (AU$5.89m market cap, or US$3.85m). Announcement • May 20
TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 2.25 million. TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 2.25 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 102,818,898
Price\Range: AUD 0.015
Discount Per Security: AUD 0.0009
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 47,181,102
Price\Range: AUD 0.015
Discount Per Security: AUD 0.0009
Transaction Features: Subsequent Direct Listing Announcement • Mar 17
TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 2.25 million. TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 2.25 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 102,818,898
Price\Range: AUD 0.015
Discount Per Security: AUD 0.0009
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 47,181,102
Price\Range: AUD 0.015
Discount Per Security: AUD 0.0009
Transaction Features: Subsequent Direct Listing Announcement • Oct 09
TrivarX Limited, Annual General Meeting, Nov 28, 2024 TrivarX Limited, Annual General Meeting, Nov 28, 2024. Location: 647 beaufort street, mount lawley, western australia., western australia. Australia Announcement • Sep 25
TrivarX Limited Appoints John H. Mathias II as Non-Executive Director, Effective 1 October 2024 TrivarX Limited announced that it has strengthened the composition of its Board with the appointment of Mr. John H. Mathias II as a Non-executive Director, effective 1 October 2024. Mr. Mathias is an accomplished healthcare focused operations and business development executive, with a clinical background in respiratory care. He has a demonstrated track record of success over a 30-year career in the US healthcare industry. Currently, he holds the role of Chief Development Officer at Medbridge Healthcare. MedBridge also has a number of professional partnerships that support adjacent services including hospital readmission reduction programs (HRRP), product and drug research, occupational health, professional services and therapeutic sleep offerings. As CDO, he plays a central role in building partnerships with stakeholders across the US healthcare system in the field of sleep medicine including hospitals, medical research institutions, clinical partnerships, and insurance companies. Prior to his role as CDO, Mr. Mathias also served as Chief Operating Officer and President of Sleep Services of America Inc., an entity of Johns Hopkins Health System, where he managed operations for sleep diagnostics and therapeutic coordination, oversaw strategic M&A and led a business turnaround which returned the division to profitability. Throughout his career, Mr. Mathias has been recognised for building and leading high-performing healthcare managers and sales teams and implementing strategic business plans to drive consistent growth in revenue and margin levels. With direct experience across several US healthcare industries, his core areas of expertise include contract management services for sleep and respiratory services, along with acute care hospital operations and developing improved patient solutions in the aged care industry. Mr. Mathias' appointment provides the Board with additional depth and expertise as it moves from clinical development towards regulatory approval and commercialisation for its proprietary MEB-001 algorithm with the effective screening of a current Major Depressive Episode (cMDE) in the US market. New Risk • Aug 30
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$3.7m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$3.7m free cash flow). Earnings have declined by 2.1% per year over the past 5 years. Revenue is less than US$1m (AU$893k revenue, or US$607k). Market cap is less than US$10m (AU$9.60m market cap, or US$6.53m). Minor Risks Share price has been volatile over the past 3 months (17% average weekly change). Shareholders have been diluted in the past year (50% increase in shares outstanding). Board Change • May 02
Less than half of directors are independent There are 4 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 4 new directors. 3 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). Chairman of Growth & Advocacy Advisory Board Peter Carlisle is the most experienced director on the board, commencing their role in 2017. Independent Non-Executive Chairman David Trimboli was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors. Announcement • May 02
TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million. TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 70,970,745
Price\Range: AUD 0.025
Discount Per Security: AUD 0.0015
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 29,029,255
Price\Range: AUD 0.025
Discount Per Security: AUD 0.0015
Transaction Features: Subsequent Direct Listing Board Change • Feb 24
Less than half of directors are independent There are 4 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 4 new directors. 3 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). Chairman of Growth & Advocacy Advisory Board Peter Carlisle is the most experienced director on the board, commencing their role in 2017. Independent Non-Executive Chairman David Trimboli was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors. Announcement • Oct 06
Medibio Limited, Annual General Meeting, Nov 29, 2023 Medibio Limited, Annual General Meeting, Nov 29, 2023, at 09:00 W. Australia Standard Time. Location: COMO The Treasury, Executive Boardroom, 1 Cathedral Avenue, Perth WA 6000 Australia Reported Earnings • Oct 02
Full year 2023 earnings released: AU$0.001 loss per share (vs AU$0.006 loss in FY 2022) Full year 2023 results: AU$0.001 loss per share (improved from AU$0.006 loss in FY 2022). Net loss: AU$3.07m (loss narrowed 76% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has fallen by 55% per year, which means it is performing significantly worse than earnings. Reported Earnings • Sep 01
Full year 2023 earnings released: AU$0.001 loss per share (vs AU$0.006 loss in FY 2022) Full year 2023 results: AU$0.001 loss per share (improved from AU$0.006 loss in FY 2022). Net loss: AU$3.12m (loss narrowed 76% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has fallen by 54% per year, which means it is performing significantly worse than earnings. Board Change • Jul 14
Less than half of directors are independent There are 4 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 4 new directors. 3 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). Chairman of Growth & Advocacy Advisory Board Peter Carlisle is the most experienced director on the board, commencing their role in 2017. Independent Non-Executive Chairman David Trimboli was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors. Reported Earnings • Feb 25
First half 2023 earnings released First half 2023 results: Net loss: AU$420.7k (loss narrowed 35% from 1H 2022). Announcement • Feb 18
Medibio Limited Appoints Christopher Ntoumenopoulos as Director Medibio Limited announced the appointment of Christopher Ntoumenopoulos as Director of the company. The date of appointment is 15 February 2023. Board Change • Nov 16
Less than half of directors are independent There are 3 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 3 new directors. 4 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). Chairman of Growth & Advocacy Advisory Board Peter Carlisle is the most experienced director on the board, commencing their role in 2017. Independent Non-Executive Chairman David Trimboli was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors. Reported Earnings • Oct 02
Full year 2022 earnings released: AU$0.006 loss per share (vs AU$0.001 loss in FY 2021) Full year 2022 results: AU$0.006 loss per share (further deteriorated from AU$0.001 loss in FY 2021). Net loss: AU$12.7m (loss widened AU$11.2m from FY 2021). Over the last 3 years on average, earnings per share has increased by 89% per year but the company’s share price has fallen by 51% per year, which means it is significantly lagging earnings. Reported Earnings • Sep 02
Full year 2022 earnings released: AU$0.006 loss per share (vs AU$0.001 loss in FY 2021) Full year 2022 results: AU$0.006 loss per share (down from AU$0.001 loss in FY 2021). Net loss: AU$12.7m (loss widened AU$11.2m from FY 2021). Over the last 3 years on average, earnings per share has increased by 89% per year but the company’s share price has fallen by 57% per year, which means it is significantly lagging earnings. Board Change • Apr 27
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 3 experienced directors. No highly experienced directors. 1 independent director (4 non-independent directors). Chairman of Growth & Advocacy Advisory Board and Non-Executive & Lead Independent Director Peter Carlisle is the most experienced director on the board, commencing their role in 2017. They were also the last independent director to join the board. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Reported Earnings • Mar 01
First half 2022 earnings: EPS in line with expectations, revenues disappoint First half 2022 results: EPS: AU$0 (up from AU$0.001 loss in 1H 2021). Net loss: AU$644.7k (loss narrowed 13% from 1H 2021). Revenue missed analyst estimates by 66%. Earnings per share (EPS) were in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 123% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings. Reported Earnings • Sep 02
Full year 2021 earnings released: AU$0.001 loss per share (vs AU$0.004 loss in FY 2020) Full year 2021 results: Net loss: AU$1.49m (loss narrowed 62% from FY 2020). Over the last 3 years on average, earnings per share has increased by 109% per year but the company’s share price has fallen by 60% per year, which means it is significantly lagging earnings. Reported Earnings • Feb 28
First half 2021 earnings released: AU$0.001 loss per share (vs AU$0.003 loss in 1H 2020) First half 2021 results: Net loss: AU$741.8k (loss narrowed 69% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 86% per year but the company’s share price has fallen by 64% per year, which means it is significantly lagging earnings. Reported Earnings • Sep 26
Full year earnings released - AU$0.0044 loss per share Over the last 12 months the company has reported total losses of AU$3.87m, with losses narrowing by 41% from the prior year. 
